Table 2.
Proportion of patients* with ≥1 lipid testing during one year from index date for all cohorts, general and stratified by baseline covariables
| SLE | DM | General Medicaid | |
|---|---|---|---|
| Cohort size (N) | 25,950 | 51,900 | 103,800 |
| General | 6,310 (24%) | 22,389 (43%) | 16,454 (16%) |
| Sex | |||
| Female | 24% | 43% | 16% |
| Male | 23% | 41% | 16% |
| Age | |||
| 18–39 | 22% | 42% | 10% |
| 40–49 | 25% | 45% | 19% |
| 50–65 | 28% | 44% | 22% |
| Outpatient Visits† | |||
| High | 32% | 54% | 20% |
| Low | 14% | 25% | 10% |
| Race/ethnicity | |||
| White | 23% | 41% | 16% |
| Black | 22% | 39% | 16% |
| Hispanic | 29% | 52% | 14% |
| Asian | 37% | 63% | 26% |
| American Indian/Alaskan Native | 19% | 35% | 13% |
| U.S. Region of residence | |||
| West | 29% | 52% | 13% |
| Northeast | 25% | 44% | 19% |
| South | 25% | 43% | 18% |
| Midwest | 20% | 35% | 14% |
| SES Quartile | |||
| 1st | 23% | 43% | 18% |
| 2nd | 24% | 42% | 16% |
| 3rd | 25% | 44% | 16% |
| 4th | 25% | 44% | 14% |
| Lupus nephritis/Diabetic nephropathy | 27% | 38% | |
| Cardiovascular disease (CVD) | |||
| Present | 28% | 45% | 33% |
| Not present | 24% | 43% | 15% |
| # Medications† | |||
| High | 35% | 57% | 24% |
| Low | 14% | 31% | 9% |
| Charlson comorbidity index† | |||
| High | 27% | 43% | 24% |
| Low | 23% | 43% | 14% |
| Glucocorticoid Use ≥10 mg/day ever | |||
| Yes | 31% | 54% | 27% |
| No | 20% | 42% | 15% |
*
Proportion described as percentage of patients with variable in cohort who received lipid testing at one year (i.e., 24% of females in the SLE cohort received lipid testing at one year).
†
High: Equal to and higher than median; Low: lower than median
Abbreviations: SLE, systemic lupus erythematosus; DM, diabetes mellitus; CVD, cardiovascular disease